Statement: the primary trial participants apply topical imiquimod to cutaneous lesions once daily on days for a total of 13 days every 28 day cycle.
Primary_evidence: INTERVENTION 1:    Treatment (Biological Therapy, Chemo)   Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.   imiquimod: Given topically   Abraxane: Given IV   laboratory biomarker analysis: Correlative studies   RNA analysis: Correlative studies   immunoenzyme technique: Correlative studies